3D Medicines, Inc. ((HK:1244)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
3D Medicines, Inc. (HK:1244) has announced a new clinical study titled ‘A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain.’ The study aims to assess the safety and efficacy of 3D1002, alone or combined with OxyContin, for managing cancer pain, a significant concern for patients with moderate to severe symptoms.
The study tests several interventions, including 3D1002 at varying doses and in combination with OxyContin. 3D1002 is an experimental drug designed to alleviate cancer pain, while OxyContin is a well-known pain management medication.
This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as its primary purpose. The study is divided into Phase IIa and IIb, each testing different combinations and dosages of the drugs.
Key dates for this study include the initial submission on January 24, 2022, and the most recent update on May 27, 2025. The study is not yet recruiting, indicating that patient enrollment is expected to start soon.
The market implications of this study could be significant for 3D Medicines, potentially boosting its stock performance if the results are positive. The study’s progress may also influence investor sentiment, especially in the competitive field of cancer pain management.
The study is ongoing, with further details available on the ClinicalTrials portal.